GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medical Developments International Ltd (ASX:MVP) » Definitions » Financial Strength

Medical Developments International (ASX:MVP) Financial Strength : 5 (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Medical Developments International Financial Strength?

Medical Developments International has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Medical Developments International's Interest Coverage for the quarter that ended in Dec. 2024 was 4.67. Medical Developments International's debt to revenue ratio for the quarter that ended in Dec. 2024 was 0.05. As of today, Medical Developments International's Altman Z-Score is 0.82.


Competitive Comparison of Medical Developments International's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medical Developments International's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Financial Strength distribution charts can be found below:

* The bar in red indicates where Medical Developments International's Financial Strength falls into.



Medical Developments International Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Medical Developments International's Interest Expense for the months ended in Dec. 2024 was A$-0.04 Mil. Its Operating Income for the months ended in Dec. 2024 was A$0.18 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$1.77 Mil.

Medical Developments International's Interest Coverage for the quarter that ended in Dec. 2024 is

Interest Coverage=-1*Operating Income (Q: Dec. 2024 )/Interest Expense (Q: Dec. 2024 )
=-1*0.182/-0.039
=4.67

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Medical Developments International's Debt to Revenue Ratio for the quarter that ended in Dec. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.377 + 1.765) / 39.974
=0.05

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Medical Developments International has a Z-score of 0.82, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 0.82 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medical Developments International  (ASX:MVP) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Medical Developments International has the Financial Strength Rank of 5.


Medical Developments International Financial Strength Related Terms

Thank you for viewing the detailed overview of Medical Developments International's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Medical Developments International Business Description

Traded in Other Exchanges
Address
4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. It manufactures and distributes the pharmaceutical drug and medical and veterinary equipment. The company provides a range of products in the areas of pain management, asthma, and resuscitation, plus veterinary equipment. It is organized into three business units: Pharmaceuticals, Medical Devices, and Veterinary products. Majority of its revenue comes from Pharmaceuticals Unit which engages in the sale of Penthrox within Australia, New Zealand, Europe the UK and some sales in Canada, the Middle East, Asia and South Africa.

Medical Developments International Headlines

From GuruFocus

Roundhill Announces Two Fund Closures

By PRNewswire PRNewswire 03-18-2022